Dabigatran in atrial fibrillation

4th April 2012 by Louise Hudman

This guideline lays out the criteria for the use of Dabigatran, a thrombin inhibitor.

It can be considered as an alternative to warfarin in non-valvular AF if at least one of the following applies:

  • Previous CVA / TIA / systemic embolism
  • LV ejection fraction < 40%
  • Heart Failure NYHA II or above
  • ≥ 75
  • ≥ 65 + DM or coronary artery disease or hypertension

It is much more expensive than warfarin, though at higher doses is more effective at reducing stroke. Its major benefits are in not having so many food and drug interactions and not needing monitoring. We will need to wait to see how this will be used locally.


Join to view the rest of this content, as well as access all the benefits of joining NASGP.



Already a member? Login to view this content.


"I have found membership very helpful during my time as a GP locum and would like to thank you very much."

Dr Louise Napier-Hemy

See the full list of features within our NASGP membership plans